UroMark—a urinary biomarker assay for the detection of bladder cancer

[1]  P. Guldberg,et al.  A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria. , 2016, European urology.

[2]  B. Lamb,et al.  Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. , 2016, Cancer treatment reviews.

[3]  A. Vlahou,et al.  Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study , 2016, Clinical Cancer Research.

[4]  K. V. van Kessel,et al.  Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria. , 2016, The Journal of urology.

[5]  M. Zeegers,et al.  Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer , 2016, PloS one.

[6]  B. Inman,et al.  Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer. , 2015, Urologic oncology.

[7]  F. Real,et al.  Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. , 2015, European urology.

[8]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[9]  Bernhard Kiss,et al.  Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non‐muscle‐invasive bladder cancer? , 2015, International journal of urology : official journal of the Japanese Urological Association.

[10]  Peter A. Jones,et al.  A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence , 2014, Clinical Cancer Research.

[11]  S. Beck,et al.  Assessment of RainDrop BS-seq as a method for large-scale, targeted bisulfite sequencing , 2014, Epigenetics.

[12]  Andrew E. Teschendorff,et al.  ChAMP: 450k Chip Analysis Methylation Pipeline , 2014, Bioinform..

[13]  Robert Lowe,et al.  Marmal-aid – a database for Infinium HumanMethylation450 , 2013, BMC Bioinformatics.

[14]  M. Ross,et al.  Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2 , 2013, Nature Communications.

[15]  E. Zwarthoff,et al.  A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine , 2013, Clinical Cancer Research.

[16]  E. Zwarthoff,et al.  Hypermethylation of the polycomb group target gene PCDH7 in bladder tumors from patients of all ages. , 2013, The Journal of urology.

[17]  E. Zwarthoff,et al.  DNA methylation-based biomarkers in bladder cancer , 2013, Nature Reviews Urology.

[18]  Jason B. Nikas,et al.  APOBEC3B is an enzymatic source of mutation in breast cancer , 2013, Nature.

[19]  Francesco Marabita,et al.  A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data , 2012, Bioinform..

[20]  P. Crispen,et al.  NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study. , 2012, The Canadian journal of urology.

[21]  G. T. Hart,et al.  Application of microdroplet PCR for large-scale targeted bisulfite sequencing. , 2011, Genome research.

[22]  H. Grossman,et al.  Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. , 2011, European urology.

[23]  Sarah Bonnin,et al.  TEQC: an R package for quality control in target capture experiments , 2011, Bioinform..

[24]  Felix Krueger,et al.  Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications , 2011, Bioinform..

[25]  Jeffrey Gahan,et al.  Photodynamic diagnosis in urology: state of the art. , 2011, Archivos espanoles de urologia.

[26]  R. Lothe,et al.  Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples , 2010, Clinical Cancer Research.

[27]  L. de Leval,et al.  Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. , 2010, European urology.

[28]  K. Frazer,et al.  Microdroplet-based PCR amplification for large scale targeted sequencing , 2009, Nature Biotechnology.

[29]  J. Kelly,et al.  Assessment and management of non-visible haematuria in primary care , 2009, BMJ : British Medical Journal.

[30]  Max Kuhn,et al.  Building Predictive Models in R Using the caret Package , 2008 .

[31]  Dieter Jocham,et al.  Photodynamic diagnosis in urology: state-of-the-art. , 2008, European urology.

[32]  Bernhard Walter,et al.  Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. , 2007, Urology.

[33]  H. Herr,et al.  Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. , 2007, The Journal of urology.

[34]  T. Ratliff.  Urine markers for bladder cancer surveillance: a systematic review. , 2005, The Journal of urology.

[35]  Li Yu,et al.  [DNA methylation and cancer]. , 2005, Zhonghua nei ke za zhi.

[36]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.

[37]  D. Shackley,et al.  The community‐based morbidity of flexible cystoscopy , 2002, BJU international.

[38]  P Schneede,et al.  Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. , 2001, Urology.

[39]  D. Neal,et al.  A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. , 2000, The Journal of urology.